Oppenheimer Reiterates Outperform on Relay Therapeutics, Lowers Price Target to $25

Benzinga · 05/06 11:58
Oppenheimer analyst Matthew Biegler reiterates Relay Therapeutics (NASDAQ:RLAY) with a Outperform and lowers the price target from $33 to $25.